The clinical success of nanomedicines demands on the development of simple
biodegradable nanocarriers that can efficiently and stably encapsulate chemotherapeutics …

Despite the great significance of clinically viable nanovehicles, very few of them exhibit
stability and high anticancer drug loading with fast intracellular drug release. Herein, we …

Doxorubicin (Dox) is commonly used to treat human malignancies, and the efficacy of Dox
can be maximized by limiting toxicity when combined with nanoparticles. PST-Dox …

As a synergistic drug combination, doxorubicin-loaded cisplatin crosslinked polysaccharide-
based nanoparticles (Dex-SA-DOX-CDDP) have demonstrated enhanced antitumor efficacy …

Polypeptide micelles, though having been proved to be an appealing nanoplatform for
cancer chemotherapy, are met with issues like inefficient drug encapsulation, gradual drug …

To overcome the limitation of conventional nanodrugs in tumor targeting efficiency, coupling
targeting ligands to polymeric nanoparticles can enhance the specific binding of nanodrugs …

For the treatment of malignant tumors, drug nanocarriers with long blood circulation time and
ability to target the tumor microenvironment are promising therapeutic abilities. In this work …

Doxorubicin (DOX), a kind of wide-spectrum chemotherapeutic drug, can cause severe side
effects in clinical use. To enhance its antitumor efficacy while reducing the side effects, two …

Targeted delivery strategies are becoming increasingly important. Herein, a novel
hyperbranched amphiphilic poly [(amine-ester)-co-(d, l-lactide)]/1, 2-dipalmitoyl-sn-glycero-3 …

Poor deep tumor penetration and incomplete intracellular drug release remain challenges
for antitumor nanomedicine application in clinical settings. Herein, a nanomedicine (RLPA …